Literature DB >> 27838635

Genetic variants of mucins: unexplored conundrum.

Sushil Kumar1, Eric Cruz1, Suhasini Joshi1, Asish Patel1, Rahat Jahan1, Surinder K Batra1,2,3, Maneesh Jain1,3.   

Abstract

Alternative gene splicing, occurring ubiquitously in multicellular organisms can produce several protein isoforms with putatively different functions. The enormously extended genomic structure of mucin genes characterized by the presence of multiple exons encoding various domains may result in functionally diverse repertoire of mucin proteins due to alternative splicing. Splice variants (Svs) and mutations in mucin genes have been observed in various cancers and shown to participate in cancer progression and metastasis. Although several mucin Svs have been identified, their potential functions remain largely unexplored with the exception of the Svs of MUC1 and MUC4. A few studies have examined the expression of MUC1 and MUC4 Svs in cancer and indicated their potential involvement in promoting cancer cell proliferation, invasion, migration, angiogenesis and inflammation. Herein we review the current understanding of mucin Svs in cancer and inflammation and discuss the potential impact of splicing in generating a functionally diverse repertoire of mucin gene products. We also performed mutational analysis of mucin genes across five major cancer types in International Cancer Genome Consortium database and found unequal mutational rates across the panel of cancer-associated mucins. Although the functional role of mucins in the pathobiology of various malignancies and their utility as diagnostic and therapeutic targets remain undisputed, these attributes need to be reevaluated in light of the potentially unique functions of disease-specific genetic variants of mucins. Thus, the expressional and functional characterization of the genetic variants of mucins may provide avenues to fully exploit their potential as novel biomarkers and therapeutic targets.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27838635      PMCID: PMC5862316          DOI: 10.1093/carcin/bgw120

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  69 in total

1.  MUC1 splice variants in human ocular surface tissues: possible differences between dry eye patients and normal controls.

Authors:  Yoannis Imbert; Douglas S Darling; Marcia M Jumblatt; Gary N Foulks; Erica G Couzin; Pamela S Steele; William W Young
Journal:  Exp Eye Res       Date:  2006-04-21       Impact factor: 3.467

2.  The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein.

Authors:  A Baruch; M Hartmann; M Yoeli; Y Adereth; S Greenstein; Y Stadler; Y Skornik; J Zaretsky; N I Smorodinsky; I Keydar; D H Wreschner
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

3.  Genomic organization and structure of the 3' region of human MUC3: alternative splicing predicts membrane-bound and soluble forms of the mucin.

Authors:  S C Crawley; J R Gum; J W Hicks; W S Pratt; J P Aubert; D M Swallow; Y S Kim
Journal:  Biochem Biophys Res Commun       Date:  1999-10-05       Impact factor: 3.575

Review 4.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

5.  MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2.

Authors:  Joseph F Grosso; Lynn M Herbert; Jennifer L Owen; Diana M Lopez
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

6.  Entactin-2: a new member of basement membrane protein with high homology to entactin/nidogen.

Authors:  N Kimura; T Toyoshima; T Kojima; M Shimane
Journal:  Exp Cell Res       Date:  1998-05-25       Impact factor: 3.905

7.  Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms.

Authors:  Lixin Zhang; Anda Vlad; Christine Milcarek; Olivera J Finn
Journal:  Cancer Immunol Immunother       Date:  2012-09-02       Impact factor: 6.968

Review 8.  Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.

Authors:  Dan Ilkovitch; Roberto Carrio; Diana M Lopez
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 9.  Genomics of alternative splicing: evolution, development and pathophysiology.

Authors:  Eric R Gamazon; Barbara E Stranger
Journal:  Hum Genet       Date:  2014-01-01       Impact factor: 4.132

10.  MUC4 gene polymorphisms associate with endometriosis development and endometriosis-related infertility.

Authors:  Cherry Yin-Yi Chang; Hui-Wen Chang; Chih-Mei Chen; Chia-Ying Lin; Chih-Ping Chen; Chih-Ho Lai; Wei-Yong Lin; Hsing-Ping Liu; Jim Jinn-Chyuan Sheu; Fuu-Jen Tsai
Journal:  BMC Med       Date:  2011-02-24       Impact factor: 8.775

View more
  14 in total

1.  Untouchable genes in the human genome: Identifying ideal targets for cancer treatment.

Authors:  Ivan P Gorlov; Olga Y Gorlova; Christopher I Amos
Journal:  Cancer Genet       Date:  2019-01-24

2.  Polymorphisms PSCA rs2294008, IL-4 rs2243250 and MUC1 rs4072037 are associated with gastric cancer in a high risk population.

Authors:  Patricio Gonzalez-Hormazabal; Rocío Retamales-Ortega; Maher Musleh; Marco Bustamante; Juan Stambuk; Raul Pisano; Hector Valladares; Enrique Lanzarini; Hector Chiong; Jose Suazo; Luis A Quiñones; Nelson M Varela; V Gonzalo Castro; Lilian Jara; Ricardo A Verdugo; Zoltan Berger
Journal:  Mol Biol Rep       Date:  2020-10-31       Impact factor: 2.316

3.  A Genome-Wide Association Study Identifies Two Novel Susceptible Regions for Squamous Cell Carcinoma of the Head and Neck.

Authors:  Hongliang Liu; Jian Wang; Robert Yu; Sanjay Shete; Erich M Sturgis; Guojun Li; Kristina R Dahlstrom; Zhensheng Liu; Christopher I Amos; Qingyi Wei
Journal:  Cancer Res       Date:  2020-04-10       Impact factor: 12.701

Review 4.  MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma.

Authors:  Shailendra K Gautam; Sushil Kumar; Andrew Cannon; Bradley Hall; Rakesh Bhatia; Mohd Wasim Nasser; Sidharth Mahapatra; Surinder K Batra; Maneesh Jain
Journal:  Expert Opin Ther Targets       Date:  2017-05-29       Impact factor: 6.902

5.  MUC4 isoforms expression profiling and prognosis value in Chinese melanoma patients.

Authors:  Jinyu Yu; Longwen Xu; Junya Yan; Jiayi Yu; Xiaowen Wu; Jie Dai; Jun Guo; Yan Kong
Journal:  Clin Exp Med       Date:  2020-03-14       Impact factor: 3.984

6.  Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-β1/FAK/ERK pathway.

Authors:  Rahat Jahan; Muzafar A Macha; Satyanarayana Rachagani; Srustidhar Das; Lynette M Smith; Sukhwinder Kaur; Surinder K Batra
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-05-16       Impact factor: 5.187

Review 7.  Unraveling mucin domains in cancer and metastasis: when protectors become predators.

Authors:  Koelina Ganguly; Sanchita Rauth; Saravanakumar Marimuthu; Sushil Kumar; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 8.  MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.

Authors:  Shailendra K Gautam; Sushil Kumar; Vi Dam; Dario Ghersi; Maneesh Jain; Surinder K Batra
Journal:  Semin Immunol       Date:  2020-01-14       Impact factor: 11.130

Review 9.  An Evolutionary Perspective on the Impact of Genomic Copy Number Variation on Human Health.

Authors:  Marie Saitou; Omer Gokcumen
Journal:  J Mol Evol       Date:  2019-09-14       Impact factor: 2.395

Review 10.  Mucinous colorectal adenocarcinoma: clinical pathology and treatment options.

Authors:  Cong Luo; Shuyi Cen; Guojun Ding; Wei Wu
Journal:  Cancer Commun (Lond)       Date:  2019-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.